title: Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland.
abstract: OBJECTIVE
  In Switzerland, fewer than 40% of hepatitis C virus (HCV) infected individuals have been diagnosed. The aim of this project was to analyse the distribution of HCV cases in order to develop better detection strategies.
  
  
  METHODS
  Historical data on the HCV-infected population in Switzerland were obtained from published literature, unpublished data and government reports. A disease progression model was used to age the infected population to 2015. The HCV distribution was then used to identify 5-year age cohorts with the highest HCV prevalence. The estimated number of cases needed to screen within an age cohort was calculated using the estimated viraemic prevalence, removing the percent previously diagnosed.
  
  
  RESULTS
  In 2015, the median age of the viraemic HCV infected population was 49 years, with 75% of the population born between 1951 and 1985. Random screening of the general population could identify one new viraemic HCV case per 159 persons screened, compared with targeted birth cohort screening, which could identify one new viraemic HCV case per 90-99 persons screened.
  
  
  CONCLUSIONS
  Considering only the direct cost of screening and treatment informing tests, targeted screening by birth cohort is more effective and cost effective than random screening in the general population.
authors.affiliation: Arud Centres for Addiction Medicine, Zürich, Switzerland.
authors.forename: Philip
authors.initials: P
authors.lastname: Bruggmann
authors.affiliation: Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland.
authors.forename: Francesco
authors.initials: F
authors.lastname: Negro
authors.affiliation: Gastroenterology Department, Ospedale Cantonale, Bellinzona, Switzerland.
authors.forename: Florian
authors.initials: F
authors.lastname: Bihl
authors.affiliation: Center for Disease Analysis, Louisville, Colorado, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Blach
authors.affiliation: Consultant, Denges, Switzerland.
authors.forename: Daniel
authors.initials: D
authors.lastname: Lavanchy
authors.affiliation: Swiss HPB (Hepato-Pancreato-Biliary) Centre and Department of Gastroenterology and Hepatology, University Hospital Zürich, Switzerland.
authors.forename: Beat
authors.initials: B
authors.lastname: Müllhaupt
authors.affiliation: Center for Disease Analysis, Louisville, Colorado, USA.
authors.forename: Homie
authors.initials: H
authors.lastname: Razavi
authors.affiliation: Division of Gastroenterology & Hepatology, Cantonal Hospital St. Gallen, Switzerland.
authors.forename: David
authors.initials: D
authors.lastname: Semela
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D016174:Hepacivirus; D006526:Hepatitis C / Q000175:diagnosis* / Q000453:epidemiology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008403:Mass Screening; D008875:Middle Aged; D019057:Quality-Adjusted Life Years; D013557:Switzerland / Q000453:epidemiology; D014766:Viremia / Q000175:diagnosis* / Q000453:epidemiology*; D055815:Young Adult